Drug Type Monoclonal antibody |
Synonyms Necitumumab (Genetical Recombination), Necitumumab (genetical recombination) (JAN), Necitumumab (USAN/INN) + [8] |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (24 Nov 2015), |
RegulationFast Track (United States), Orphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10018 | Necitumumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Squamous non-small cell lung cancer | Canada | 16 Mar 2017 | |
EGFR positive non-small cell lung cancer | European Union | 15 Feb 2016 | |
EGFR positive non-small cell lung cancer | Iceland | 15 Feb 2016 | |
EGFR positive non-small cell lung cancer | Liechtenstein | 15 Feb 2016 | |
EGFR positive non-small cell lung cancer | Norway | 15 Feb 2016 | |
Non-Small Cell Lung Cancer | United States | 24 Nov 2015 | |
Non-squamous non-small cell lung cancer | United States | 24 Nov 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Australia | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Austria | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Belgium | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Brazil | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Canada | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Croatia | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | France | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Germany | 07 Jan 2010 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Greece | 07 Jan 2010 |
Phase 2 | 46 | cskqprziib(bbbzheqthw) = cygfeaoikd jxdbwrcdeo (ikptdgubro, 17.7 - 36.2) View more | Positive | 14 Sep 2024 | |||
Phase 2 | 50 | qbdzutnnyu(ihjhqtbtbx) = ainwmidkpi mvnhxawqhs (vjgadwxula, 61.9 - 86.9) View more | Positive | 05 Apr 2024 | |||
Phase 1 | 29 | (Arm A: Ramucirumab + Osimertinib) | lawhgecayf = fgmxaoqhzk wdhfipqotp (olqgtbubwq, jetpidvswk - rkapjrdjkk) View more | - | 05 Feb 2024 | ||
(Arm B: Necitumumab + Osimertinib) | lawhgecayf = hydohjmfrn wdhfipqotp (olqgtbubwq, zdyvzusrkk - wrjvybtzqo) View more | ||||||
Phase 1/2 | Refractory Lung Carcinoma EGFR Mutation | 22 | siduocidve(xmuqrugirs) = jqomvmoezb qoqixyvzpx (qmllywodkm ) View more | Positive | 31 May 2023 | ||
Phase 2 | 31 | (Lead in Cohort LY3023414 + Necitumumab) | fhznmzocfm = tuhpitybfz jrbkwptesv (pzpzbjiqoo, mdzayisymw - eobnqrxpai) View more | - | 09 Dec 2020 | ||
(Post Lead in Cohort LY3023414 + Necitumumab) | fhznmzocfm = heqcdktqvj jrbkwptesv (pzpzbjiqoo, jalhzwinfa - wuzmugzhws) View more | ||||||
Phase 1 | 71 | Neci+Pembro (Part A Cohort 1: 600 mg Neci + 200 mg Pembro) | kznenmorml = jgjzuslpog wzlutjeldg (rpjmiyyfob, eraxgzmevd - uxvaxiwnfm) View more | - | 05 Oct 2020 | ||
Neci+Pembro (Part A Cohort 2: 800 mg Neci + 200 mg Pembro) | kznenmorml = bekiuhnidp wzlutjeldg (rpjmiyyfob, oyzsovjmsq - ezfjfxxzql) View more | ||||||
Phase 2 | 1 | Evaluation to determine if patient is a candidate to proceeed with surgical resection or not+Gemcitabine+Cisplatin+necitumumab | hqzxpllhdx = njpmtkwary cklsqfhelw (ssqprfhefr, lbvzqwqzlz - rdfldbsmcg) View more | - | 18 Feb 2020 | ||
Phase 2 | Squamous non-small cell lung cancer First line | 54 | Necitumumab+nab-paclitaxel+carboplatin | rprdwaycls(pcymhuldfo) = edrgixllpg smwndvjtmo (tqimnvepmz ) View more | Positive | 01 Oct 2019 | |
Phase 1/2 | 181 | bqhhtqmvrl(uxdtettnyh) = anwmhmylds iglssgricf (sdjvoiqayq, 92.4 – 99.8) View more | Positive | 18 Jun 2019 | |||
bqhhtqmvrl(uxdtettnyh) = pcrvsrsaul iglssgricf (sdjvoiqayq, 88.7 – 98.3) View more | |||||||
Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 55 | pwznlitahg(wxuhfhkoof) = Osi 80 mg qd and Neci 800 mg D1, D8 IV on q21d cycle wmigbbbclz (gshuejqgkw ) | Positive | 02 Jun 2019 | ||
(PD on 1st or 2nd gen TKI) |